PDSB / PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study

Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline can more_horizontal

PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck more_horizontal

PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeli more_horizontal

FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing more_horizontal

PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival ra more_horizontal

PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients. more_horizontal

PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer pati more_horizontal

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a more_horizontal